ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Biologicals"

  • Abstract Number: 0003 • ACR Convergence 2020

    Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations

    Quinn Pritchett1, Rebecca Overbury1, Dorota Lebiedz-Odrobina1, Julie Thomas1, Tawnie Braaten2, Stacey Clardy1, Marc Elgort3, Emily Spivak1, Patricia Slev3, Lisa Peterson3 and Tracy Frech4, 1University of Utah, Salt Lake City, UT, 2University of Utah, Salt Lake City, 3ARUP, Salt Lake City, UT, 4University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT

    Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
  • Abstract Number: 0230 • ACR Convergence 2020

    Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial

    Nora G. Singer1, Shalini V. Mohan2, Jeffrey Yourish3, Jian Han2, Michael Edwardes4 and Margaret Michalska3, 1Case Western Reserve University and MetroHealth System, Cleveland, 2Genentech, South San Francisco, CA, 3Genentech, Inc., South San Francisco, 4Everest Clinical Research, Ontario, Canada

    Background/Purpose: In patients with rheumatoid arthritis (RA), subcutaneous tocilizumab (TCZ-SC) is administered every 2 weeks (q2w) or every week (qw), based on the patient’s weight…
  • Abstract Number: 0356 • ACR Convergence 2020

    Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity

    Laure Gossec1, Philip Mease2, Alice Gottlieb3, Deepak Assudani4, Jason Coarse5, Barbara Ink6 and Laura Coates7, 1Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 4UCB Pharma, Slough, United Kingdom, 5UCB Pharma, Raleigh, NC, 6UCB Pharma, Slough, 7University of Oxford, Oxford, United Kingdom

    Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…
  • Abstract Number: 0516 • ACR Convergence 2020

    Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial

    Sebastian Unizony1, Shalini V. Mohan2, Jian Han2 and John H. Stone1, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Genentech, South San Francisco, CA

    Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
  • Abstract Number: 0743 • ACR Convergence 2020

    Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis

    William Robinson1, Chun Wu2, Sarah Hu2, Sean Connolly2 and Sumanta Mukherjee2, 1Stanford University School of Medicine, Stanford, CT, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: ACPAs are sensitive, highly specific markers of RA. Current tests cannot differentiate ACPA+ RA subtypes. Fine-specificity ACPAs (FS) can distinguish between ACPA+ RA subtypes…
  • Abstract Number: 0827 • ACR Convergence 2020

    Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis

    Thomas Huizinga1, Ernest Choy2, Amy Praestgaard3, Hubert van Hoogstraten4, Patrick R LaFontaine3, Patricia Guyot5, Daniel Aletaha6, Ulf Müller-Ladner7, Yoshiya Tanaka8, Jeffrey R Curtis9 and Roy Fleischmann10, 1Leiden University Medical Center, Leiden, Netherlands, 2CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 3Sanofi, Cambridge, MA, 4Sanofi, Bridgewater, NJ, 5Sanofi, Chilly-Mazarin, France, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 7Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, 8The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 9Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 10Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
  • Abstract Number: 0906 • ACR Convergence 2020

    Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study

    Atul Deodhar1, Laure Gossec2, Philip Mease3, Jason Coarse4, Heather Edens5, Natasha de Peyrecave6, Deepak Assudani6, Barbara Ink7 and Christopher Ritchlin8, 1Oregon Health & Science University, Portland, OR, 2Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4UCB Pharma, Raleigh, NC, 5UCB Pharma, Smyrna, GA, 6UCB Pharma, Slough, United Kingdom, 7UCB Pharma, Slough, 8Department of Medicine, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
  • Abstract Number: 1236 • ACR Convergence 2020

    Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials

    Sebastian Unizony1, Joseph Dang2, Jian Han3, Margaret Michalska2 and Jennie H. Best2, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Genentech, Inc., South San Francisco, 3Genentech, South San Francisco, CA

    Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
  • Abstract Number: 1427 • ACR Convergence 2020

    Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach

    Allyson Egan1, Pasupathy Sivasothy2, Robin Gore3, Caroline Owen3, Marcos Del Martinez Pero4, Rachel Jones4, Lisa Willcocks4, Rona Smith4, Stella Burns4 and David Jayne5, 1Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., London, United Kingdom, 2Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., Cambridge, England, United Kingdom, 3Department of Respiratory medicine, Addenbrooke's Hospital, Cambridge, Cambridge, United Kingdom, 4Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., Cambridge, 5Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom

    Background/Purpose: EGPA is a small vessel vasculitis characterized by the presence of tissue eosinophilia, necrotizing vasculitis and granulomatous inflammation1. In the randomized, placebo-controlled MIRRA trial…
  • Abstract Number: 1826 • ACR Convergence 2020

    ­Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study

    Ronald van Vollenhoven1, Bevra Hahn2, George Tsokos3, Peter Lipsky4, Robert Gordon5, Kaiyin Fei6, Kim Hung Lo7, Marc Chevrier8, Qing Zuraw9, Pamela Berry10, Chetan Karyekar10 and Shawn Rose11, 1Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 2University of California Los Angeles, Encino, CA, 3Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, 4RILITE Foundation, Charlottesville, VA, 5Janssen Research & Development, LLC, Chester Springs, PA, 6Janssen Research & Development, LLC, Spring House, PA, 7Janssen Research & Development, LLC, Spring House, 8Janssen Research & Development, LLC, Collegeville, PA, 9Janssen Research & Development, LLC, Wayne, PA, 10Janssen Global Services, LLC, Horsham, PA, 11Janssen Research & Development, LLC, Princeton Junction, NJ

    Background/Purpose: Both IL-12 and IL-23 have been implicated in the pathogenesis of SLE. In a phase 2 study, treatment with the anti-IL-12/23 p40 monoclonal antibody…
  • Abstract Number: 0008 • ACR Convergence 2020

    COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review

    Akhil Sood1, Arbi Galestanian1, Vijaya Murthy2, Emilio Gonzalez1 and Mukaila Raji1, 1University of Texas Medical Branch, Galveston, TX, 2University of Texas Medical Branch, League City, TX

    Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…
  • Abstract Number: 0231 • ACR Convergence 2020

    Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset

    Helen Cooley1, Tegan Smith2, Peter Youssef3, Kathleen Tymms4, David Mathers5, Sabina Ciciriello6, Hedley Griffiths7, Catherine OSullivan2 and Geoffrey Littlejohn8, 1Hobart Private Hospital, Hobart, TAS, Taroona, Australia, 2OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, 3University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, 4Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, 5Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, 6Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, 7Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia, 8Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia

    Background/Purpose: In Australia the cost of biological/targeted synthetic DMARDs (b/tsDMARDs) for treatment of RA is subsidized if the patient has documented high levels of clinical/laboratory…
  • Abstract Number: 0358 • ACR Convergence 2020

    Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study

    Elke Riechers1, Uta Kiltz2, Jan Brandt-Jürgens3, Peter Kästner4, Daniel Peterlik5 and Hans-Peter Tony6, 1Hannover Medical School, Hannover, Germany, 2Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 3Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, 4Ambulantes Rheumazentrum, Erfurt, Germany, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

    Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…
  • Abstract Number: 0555 • ACR Convergence 2020

    Utilization and Adherence Among Infliximab Biosimilar Initiators in a U.S. National Commercial Insurance Database

    Sujith Sarvesh1, Joseph Alanaeme1, Jeffrey R Curtis2 and Huifeng Yun2, 1University of Alabama at Birmingham, BIrmingham, AL, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Infliximab Biosimilar, the first biosimilar to infliximab, was approved for multiple indications in the U.S. in 2016. Since the utilization of biosimilar in the…
  • Abstract Number: 0798 • ACR Convergence 2020

    A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92

    Roy Fleischmann1, Daniel Alvarez2, Amy Bock3, Carol Cronenberger4, Ivana Vranic5, Wuyan Zhang6 and Rieke Alten7, 1Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2Pfizer, Collegeville, PA, 3Pfizer, Cambridge, MA, 4Pfizer, Collegeville, 5Pfizer, Tadworth, United Kingdom, 6Pfizer, New York, 7Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany

    Background/Purpose: To evaluate the long-term safety, immunogenicity (IG), and efficacy of the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF), in patients (pts) with moderate to severe active…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.